ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements with these filters
Viyash Scientific announced postal ballot results. Shareholders approved the appointments of Amit Jain and Abhiroop Jayanthi as Non-Executive Directors.
Viyash Scientific shared its Investor Day presentation, outlining its integrated pharmaceutical strategy and leadership profile. No new financial or operational data were disclosed.
Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.
Viyash Scientific acquired 100% of Italy's BioForLife for ₹188 Crore. The strategic move strengthens its European companion animal health presence and global growth footprint.
Viyash Scientific acquired 100% of BioForLife Italia for €16.975 million (₹185.03 Crore). The acquisition strengthens the company's companion animal health presence in the Italian market.
Viyash Scientific Limited issued a postal ballot notice for director appointments and a one-time incentive. Shareholders will vote on a ₹4.00 Crore performance bonus.
Viyash Scientific Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report details regulatory compliance and historical governance observations.
India Ratings withdrew its rating on Viyash Scientific's ₹35 Crore bank facilities at the company's request. ICRA upgraded its rating to [ICRA] AA- (Stable).
Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.
Viyash delivered a breakout FY26 with Q4 EBITDA crossing 200cr, marking a successful business integration.
Viyash Q4 FY26 revenue reached ₹9,200 Mn with 21.7% EBITDA margins. Management highlights successful integration and a deleveraged balance sheet.
Viyash Scientific reported FY26 revenues of ₹3,420.3 Crore, with PAT growing 1324%. Strong Q4 performance and merger synergies indicate a solid foundation for future growth.
Viyash Scientific Ltd reported revenue from operations of ₹920 Cr (+19.1% YoY) and net profit of ₹66.4 Cr for Q4 FY26.
Viyash Scientific approved its FY 2025-26 audited financial results and a new employee stock option scheme. No dividend was recommended to conserve resources for growth.
Viyash Scientific Limited reported the sad demise of Mr. Phillip Trott, AVP – Legal and Compliance. This senior management departure was effective as of May 15, 2026.